adenoviral vector neoantigen vaccine

Adenoviral vector neoantigen vaccines are a form of personalized cancer immunotherapy designed to stimulate a robust T-cell response against tumor-specific mutations (neoantigens). These vaccines utilize non-replicating adenoviral vectors (such as Ad5, ChAdOx1, or ChAd63) to deliver genetic material encoding multiple neoepitopes identified through genomic sequencing of a patient's tumor. Upon administration, the viral vector infects host cells, leading to the expression and presentation of these neoantigens on MHC molecules. This process activates both CD4+ and CD8+ T cells, potentially overcoming tumor-induced immunosuppression and providing long-term immunological memory. Key developers in this space include Gritstone bio and Nykode Therapeutics, with applications primarily in solid tumors like colorectal, lung, and pancreatic cancers.

Other names

adenovirus-based neoantigen vaccinepersonalized adenoviral neoantigen vaccineAdV-neoantigen vaccine